Skip to main content

Table 1 Baseline information on the patients with AGel amyloidosis in the FIN-GAR phase II registry

From: Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study

Number of patients

261

Gender distribution

183 (70%) female, 78 (30%) male

Mean age of the patients

62.7 years (range 26.3–85.8 years)

Median age of the patients

64.7 years (interquartile range 54.9–71.2 years)

Mean age at diagnosis of AGel amyloidosis

40.7 years (range 10.4–68.7 years)

Genetic testing done

138 (53%)

Follow-up time after FIN-GAR phase I

4.9 years (range 4.1–5.6 years)